Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

Tryp Therapeutics Inc

Tryp Therapeutics CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS. Gilligan says Tryp Therapeutics is taking a unique approach with their product, TRP-8803, which is an IV infusion of psilocin, an active metabolite of psilocybin. Currently, Gilligan says the company is using oral psilocybin in their studies while preparing for the use of TRP-8803. Tryp Therapeutics recently secured a $2.4 million private placement that Gilligan says will allow the company to continue their research and upcoming clinical trials. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 22, 2023 01:54 PM Eastern Daylight Time

Video

News Release

1606 Corp shares details of sharp growth and distribution for Brio Nutrition CBD products

1606 Corp.

1606 Corp CEO Greg Lambrecht joins Proactive's Natalie Stoberman to share how the company's Brio Nutrition line of CBD products has been growing to meet enhanced demand. Lambrecht says since the acquisition of Brio, the company has secured significant orders from existing accounts and partnered with Cool Blue Distribution to access shelf space in over 800 CBD stores. Brio is currently fulfilling a $150,000 order with anticipation of further substantial orders in the near future. Lambrecht adds that to meet this growing demand, the company is ensuring a six-month inventory supply. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

May 22, 2023 01:16 PM Eastern Daylight Time

Video

The Humane Society of the United States Addresses the Pet Poverty Crisis

YourUpdateTV

Most people are aware of how poverty and structural inequality create challenges and barriers to accessing healthy food, education, jobs, health care and housing and how inflation is only making the crisis worse. Pet resources are no different. Many families are struggling to afford and access veterinary care, food and supplies for their beloved pets. More than 20 million pets live in poverty - three times as many pets live in poverty as enter shelters every year. This is a long overlooked national crisis exacerbated by inflation and the economy. Recently, Kitty Block, President and CEO of the Humane Society of the United States, participated in a nationwide satellite media tour to discuss the launch of the More Than a Pet campaign and how the organization is addressing the crisis. A video accompanying this announcement is available at: https://youtu.be/GdaZXktSjNI Over the past 20 years, the Humane Society of the United States has helped half a million pets and their families by providing veterinary care and supplies at no cost, keeping families and pets together in over 50 communities across the U.S. Without these services, families are often forced to make choices about sacrificing their own needs, even food and medications for themselves, to prioritize care for their pet. No family should ever have to make that choice. Since 2002, the Humane Society of United States’ Pets for Life and Rural Area Veterinary Services programs have been helping pet owners across the U.S. by providing food, supplies and services for their cats and dogs at no cost. It is critical to close the gap that exists for people and pets in underserved areas. With the new campaign called “More Than a Pet,” the HSUS is sounding an alarm about this crisis that is only getting worse. The Humane Society of the United States is offering these tips for people to support their communities: Advocate for keeping pets and their people together by signing the HSUS petition to close the pet equity gap. Your voice can make a big impact for all animals. Volunteer with the Humane Society of the United States’ Pets for Life and Rural Area Veterinary Services programs, which increase access to pet care for underserved communities. Donate pet food to your local shelter or pet food pantry. If you know of a neighbor in need, offer to help drive them to a veterinary appointment, foster their pet temporarily or provide a bag of their pet’s favorite food to help close the access to pet care gap. The HSUS is inviting the public to show their support for this campaign by sharing why their animal companion is #MoreThanAPet to them, at humanesociety.org/morethanapet. Campaign partner Smalls is donating a bowl of food for every photo shared, up to $1M, to pets and their families in need. Learn More and Get Involved About Kitty Block Kitty Block is the chief executive officer and president of the Humane Society of the United States and also chief executive officer of Humane Society International. She leads the nation's most effective animal protection organization in the fight for all animals. Block was named president and CEO of the Humane Society of the United States in January 2019, becoming the first woman to hold the position in the organization’s history. Block first joined the HSUS as a legal investigator in 1992 and was instrumental in bringing cruelties such as horse slaughter and the killing of dogs and cats for their fur in China to light. She led the HSUS’s efforts to secure protections for dolphins with successful litigation and landmark dolphin-safe tuna legislation. In addition, she was one of the architects of a successful lawsuit over commercial whaling brought against Japan by Australia in the International Court of Justice. She has served as an adviser to the White House on trade and the environment, and she has served multiple elected terms on the International Dolphin Conservation Agreement International Review Panel, which works with governments on monitoring violations of the agreement. Block received a law degree from The George Washington University in 1990 and a bachelor’s degree in communications and philosophy from the University of New Hampshire in 1986. She is a lifelong animal lover who helped her mother rescue and care for pets and other animals in need as a child. Block lives in Washington, D.C., with her husband and daughter, their street dog rescue, Lilly, and rescue cats, Misti and Storm Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 22, 2023 10:15 AM Eastern Daylight Time

Video

Doceree Expands Executive Team As the Company Continues Expansion

Doceree

Doceree, a leading global platform building solutions for healthcare professionals (HCPs) through programmatic messaging with proprietary data tools, has brought on industry veteran Vijay Adapala to serve as Executive Vice President, Global Supply Partnership. Adapala plays a key role in expanding Doceree’s strategic supply-side platform (SSP) partnerships to extend the company’s network as it continues to expand its global footprint. “A key component of Doceree’s growth strategy is establishing partnerships with top tier supply side platforms (SSP) and tech companies to reach new markets and scale the existing ones,” said Harshit Jain MD, Founder and Global CEO, Doceree. ''Vijay's extensive and diverse experience in launching and scaling ad tech businesses, and developing global go-to market strategies makes him ideal to spearhead Doceree’s partner expansion initiatives. Joining at a crucial juncture when we are aggressively expanding our footprint globally, Vijay’s methodical approach will help us forge tactical and meaningful collaborations in the healthcare category, crucial to fuel our growth.” Adapala is a seasoned executive with 20+ years of experience in ad tech, digital media, and consumer tech. At Doceree, Adapala will oversee the end-to-end global supply partnerships, identify new opportunities for partnerships with healthcare platforms and publishers, and collaborate with cross-functional teams to launch and scale new service offerings for partners. Prior to joining Doceree, Adapala served as the GM at Amazon Publisher Services for Enterprise and SMB, web and mobile app publishers, where he led the strategic vision, successfully launched and scaled Amazon's ad tech solutions, and spearheaded global expansion strategies. "Doceree is transforming programmatic healthcare advertising by delivering hyper-relevant, real-time messages to Healthcare Professionals to improve patient outcomes," said Vijay Adapala. "Partnerships will play a pivotal role in reaching new audiences and delivering impactful results. I'm thrilled to collaborate with partners to enhance the HCP experience while driving their business growth." Docoree has the largest global network of HCP-only platforms for programmatic messaging, transforming the digital communication landscape in the healthcare industry. The company has recently partnered with Hello Health Group that combines the world-class HCP targeting and reach capabilities of Doceree with Hello Health’s leading patient and consumer reach and engagement solutions. To learn more about Doceree, please visit https://doceree.com/us/. About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Kite Hill PR Kerriann Becker kerriann@kitehillpr.com Company Website https://doceree.com/us/

May 22, 2023 09:00 AM Eastern Daylight Time

UAT Group Reached Agreement with Strategic Capital Partner

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (OTC: UATG) announced today that it has reached an agreement with a strategic capital partner to support the growth of its subsidiary Ossifix Orthopedics. The private equity firm specializes in the medical field. The firm’s focus provides strategic growth capital and works with existing management to increase sales, benefiting both its own investors and value for all Ossifix shareholders. As part of the agreement, the new partner will become a nine percent stakeholder in Ossifix Orthopedics and will provide up to $2 million in funding capital. The firm will also provide additional value such as its investors and relationships to include an extensive portfolio of surgeons, medical facilities and knowledgebase, which will be utilized to further expand marketing and sales for Ossifix. Chief Financial Officer, Thomas Crom stated, “Although this reduces our ownership in Ossifix it dramatically increases Ossifx capability to move forward without any dilution to UATG’s shareholders. This Ossix transaction illustrates the creative ways UATG can fund its subsidiaries without diluting its current UATG shareholders. This type of funding is complex and time-consuming but illustrates Ossifix’s intrinsic value is now being recognized by others.”. This announcement on Friday came amid growing optimism among the Company’s executives that the traction the UAT Group conglomerate has gained in the first half of the year will exceed its expectations for the year; positioning it for a remarkable year. The investment into Ossifix contributes to the Company's consolidated growth initiatives which include augmenting existing product offerings and service capabilities of its subsidiaries as well as positioning infrastructure resources in support of planned expansion. UAT Group Chairman, Alex Umbra commented, “As always, UAT Group stands ready to support each of our subsidiaries, in any way necessary, as we capitalize on the values we create together. This new relationship will not only provide strategic capital but will continue to support growth objectives that will bolster shareholder value, streamline balance sheet debt and enable verticals to be realized sooner”. About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com For more information about Ossifix Technologies, go here: https://ossifixtech.com/ NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

May 19, 2023 08:00 AM Eastern Daylight Time

Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead Securities to roll up its subsidiary Evolutionary Biologics and other regenerative medicine and regenerative biologic products companies with NO DILUTION to the Emergent Shareholders with a planned $10 million initial capital raise and public offering and application for listing on NASDAQ or NYSE/AMEX. Emergent’s subsidiary, Evolutionary Biologics, and the new brand called Maximus Men’s Health, along with Juventix Regenerative Medical and Interactive Practice Solutions and Nanosthetic. Subsequent to the IPO, Emergent plans to distribute the shares received by Emergent from the sale of Evolutionary Biologics as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Such a dividend would only occur after Emergent files a Registration Statement with the SEC and it is declared effective. Any potential taxable event resulting from such a dividend would be the responsibility of each individual shareholder, and Emergent advises each shareholder to consult with their professional advisors, and makes no representation as to the taxable or nontaxable event. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Boustead Securities is a world class financial organization. They approached us to participate in rolling up a series of regenerative biologics into a brand-new IPO. When you look at the effect that this transaction, and the previously announced PharmaZu transaction, will have on EMGE, it's amazing. We see this as a great way to maximize valuation for our Company and take EMGE to the next level.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 18, 2023 09:00 AM Eastern Daylight Time

Image

Oxford Cannabinoid Technologies reaches milestone with phase 1 trial approval for pain relief drug

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, is a significant milestone for the company. Sowemimo-Coker said recruitment for the trial has already begun, with completion expected in the third quarter of 2023. The drug targets chemotherapy-induced peripheral neuropathy (CIPN) and has the potential for other indications like irritable bowel syndrome (IBS) and other neuropathy. The phase 1 trial focuses on safety and will pave the way for phase 2 trials in other indications, she added. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 18, 2023 07:21 AM Eastern Daylight Time

Video

Medinotec creating expansion path for U.S. manufacturing and distribution of niche medical devices

Medinotec Inc

Medinotec CFO Pieter van Niekerk joins Natalie Stoberman from the Proactive studio to discuss how the company's reach in niche medical device manufacturing and distribution is growing in North America. Medinotec is a US-based company with a primary investment in DISA Medinotec, a South African medical device manufacturing and distribution company that is a global leader in tracheal non-occlusive airway dilation technology and medical device design, manufacture and distribution. van Niekerk says the company has taken recent steps to expand in the North American market by obtaining FDA approval for their unique non-occlusive device, as well as listing on the OTCQX market in March of 2023. van Niekerk adds that the company plans to diversify their medical devices through R&D projects, acquisitions, and partnerships, aiming to grow revenue streams and expand their product range. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2023 11:05 AM Eastern Daylight Time

Video

PathAI Announces IBD Explore, an AI-powered Histopathology Panel to Unlock Insights for Ulcerative Colitis from the Inflammatory Microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of IBD Explore 1, an artificial intelligence-powered panel of human interpretable features (HIFs) offering unprecedented resolution of the inflammatory microenvironment from H&E whole-slide images. IBD Explore uses more than 600 histopathology features to spatially characterize the inflammatory microenvironment, giving drug developers and clinical researchers the ability to unlock insights to inform the next phase of targeted drug development in ulcerative colitis (UC). According to the Centers for Disease Control (CDC), an increasing number of American adults have faced diagnosis of either UC or Crohn’s disease, known collectively as Inflammatory bowel disease (IBD) over the past two decades. Over the past few decades the global prevalence of UC and Crohn's disease, known collectively as inflammatory bowel disease (IBD) has increased. A Lancet study 2 found that the prevalence increased from 1990 with 79.5 per 100,000 population with IBD to 84.3 per 100,000 population in 2017. Despite this, remission rates for UC drugs have not surpassed 30% 3 and more than 30% of UC patients stop biologic therapy within 12-18 months due to lack or loss of efficacy. 4 These observations underscore the need for biomarkers such as histologic signatures to aid in drug development and patient management. Previous research found histologic measures of response to be a better predictor of drug efficacy for relapse-free survival in UC patients than endoscopy alone. 5 IBD Explore allows researchers enhanced histologic visibility, with the ability to structure and analyze spatial measures on a scalable platform, allowing insights to inform future trials. “IBD Explore provides visibility down to each individual cell in the inflammatory tissue environment and HIFs, and a level of granularity that we’ve never had,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “This level of detail helps researchers identify patient subtypes and develop customized therapeutics with the hopes of greater efficacy and increased remission for UC patients.” In addition to IBD Explore, PathAI also offers automated, AI-powered Geboes scoring with its tool AI Measurement of Histological Index for Ulcerative Colitis, or AIM-HI™UC. Combined, IBD Explore and AIM-HI UC provide IBD drug developers a complete histology solution for translational research and clinical development. “The utilization of AI-powered pathology has the potential to tremendously benefit researchers in drug discovery and clinical development by reducing trial risk and enhancing therapy differentiation,” said Mike Montalto, Ph.D., chief scientific officer at PathAI. “Our suite of AI-powered solutions can reduce the noise in histological-based endpoints for IBD clinical trials and therefore isolate true drug effect. In collaboration with our biopharma partners, we aim to accelerate precision medicine options for millions of patients with UC.” To learn more about IBD Explore, visit www.IBDExplore.com Footnotes 1 IBD Explore is for research use only. Not for use in diagnostic procedures. 2 The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. October 2020. | https://doi.org/10.1016/S2468-1253(19)30333-4 3 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 4 Factors Associated with Biologic Discontinuation in Patients with Inflammatory Bowel Disease in TARGET-IBD. The American Journal of Gastroenterology 115():p S7, December 2020. | DOI: 10.14309/01.ajg.0000722904.81509.45 5 Breaking the therapeutic ceiling in drug development in ulcerative colitis. May 2021. | https://doi.org/10.1016/S2468-1253(21)00065-0 About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to be a rapidly expanding organization comprised of innovative thinkers from around the globe, For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

May 17, 2023 10:00 AM Eastern Daylight Time

1 ... 103 104 105 106 107 ... 250